ReviewCurrent treatment options in oncology2015
Surgical Options in the Treatment of Lower Gastrointestinal Tract Cancers.
Review in Current treatment options in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is the fourth most common cancer in the USA with the second highest mortality. Early detection with screening endoscopy, in addition to improvement in treatment modalities lead to higher overall survival rates. Treatment of localized colon cancer comprises of surgical resection with en bloc lymphadenectomy. Adjuvant therapy is determined by final pathologic stage. However, treatment of rectal cancer is more complex and is determined by the clinical pathologic stage. Neoadjuvant chemoradiation therapy is an important component to treatment to decrease the risk of local recurrence. As with colon cancer, adjuvant chemotherapy is dependent on the pathologic stage. Newer technologies are being utilized in both colon and rectal cancer including minimally invasive procedures and sphincter preservation procedures. Anal squamous cell carcinoma (SCC) is the most common histologic subtype of anal canal tumors. Anal SCC is most commonly seen in patients with HPV infections. Prior to the 1970s, anal SCC was treated with abdominoperineal resection and end colostomy. Nigro and colleagues utilized chemoradiation to treat anal SCC with response rates as high as 80%. This allows majority of patients to avoid an APR with permanent colostomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.